Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar typhi

Clinical and Vaccine Immunology

Volumn 18, Issue 3, 2011, Pages 460-468

  Rondini, Simona ^a   Micoli, Francesca ^a   Lanzilao, Luisa ^a   Hale, Christine ^b   Saul, Allan J ^a   Martin, Laura B ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VECTOR; CITROBACTER FREUNDII POLYSACCHARIDE; DIPHTHERIA TOXIN; GLYCOCONJUGATE; IMMUNOGLOBULIN G; MUTANT PROTEIN; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLOGICAL ACTIVITY; CITROBACTER FREUNDII; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROVOCATION TEST; SALMONELLA TYPHI; SEROTYPE; TYPHOID FEVER; VACCINE FAILURE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL PROTEINS; CITROBACTER FREUNDII; FEMALE; MICE; MICE, INBRED BALB C; POLYSACCHARIDES, BACTERIAL; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE;

EID: 79952565597     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00387-10     Document Type: Article

References (44)

1. Baker, P. J. 1992. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J. Infect. Dis. 165(Suppl. 1):S44-S48.
2. Crump, J. A., S. P. Luby, and E. D. Mintz. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82:346-353.
3. Daniels, E. M., R. Schneerson, W. M. Egan, S. C. Szu, and J. B. Robbins. 1989. Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect. Immun. 57:3159-3164.
4. Daum, R. S., et al. 1997. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis. 176:445-455.
5. Fernandez, C., and G. Moller. 1978. Immunological unresponsiveness to native dextran B512 in young animals of dextran high responder strains is due to lack of Ig receptors expression. Evidence for a nonrandom expression of V-genes. J. Exp. Med. 147:645-655.
6. Fraser, A., E. Goldberg, C. J. Acosta, M. Paul, and L. Leibovici. 2007. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. 2007(3):CD001261.
7. Gonzalez-Fernandez, A., J. Faro, and C. Fernandez. 2008. Immune responses to polysaccharides: lessons from humans and mice. Vaccine 26:292-300.
8. Hale, C., et al. 2006. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. Vaccine 24:4312-4320.
9. Ivanoff, B., M. M. Levine, and P. H. Lambert. 1994. Vaccination against typhoid fever: present status. Bull. World Health Organ. 72:957-971.
10. Jackson, L. A. M., et al. 2009. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28:86-91.
11. Jang, H., et al. 2008. Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor. J. Biotechnol. 135:71-77.
12. Jones, C., and X. Lemercinier. 2002. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J. Pharm. Biomed. Anal. 30:1233-1247.
13. Khan, M. I., R. L. Ochiai, and J. D. Clemens. 2010. Population impact of Vi capsular polysaccharide vaccine. Expert. Rev. Vaccines 9:485-496.
14. Kossaczka, Z., et al. 1997. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
15. Kutter, E., and A. Sulakvelidze. 2004. Appendix: working with bacteriophages, p. 485. In E. Kutter and A. Sulakvelidze (ed.), Bacteriophages: biology and applications. CRC Press, Boca Raton, FL.
16. Landy, M. 1954. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am. J. Hyg. 60:52-62.
17. Lederberg, J. 1950. Isolation and characterization of biochemical mutants of bacteria. Methods Med. Res. 3:5-22.
18. Mai, N. L., et al. 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
19. Meynell, E., and G. G. Meynell. 1964. Bacteriogical culture media, p. 41. In Theory and practice in experimental bacteriology. Cambridge University Press, Cambridge, United Kingdom.
20. Micoli, F., et al. 2011. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29:712-720.
21. Ochiai, R. L., et al. 2008. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull. World Health Organ. 86:260-268.
22. Ou, J. T., L. S. Baron, F. A. Rubin, and D. J. Kopecko. 1988. Specific insertion and deletion of insertion sequence 1-like DNA element causes the reversible expression of the virulence capsular antigen Vi of Citrobacter freundii in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85:4402-4405.
23. Parry, C. M., T. T. Hien, G. Dougan, N. J. White, and J. J. Farrar. 2002. Typhoid fever. N. Engl. J. Med. 347:1770-1782.
24. Peeters, C. C., A. M. Tenbergen-Meekes, J. T. Poolman, B. J. Zegers, and G. T. Rijkers. 1992. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 10:833-840.
25. Polotsky, V. Y., R. Schneerson, D. Bryla, and J. B. Robbins. 1994. Immunogenicity of two types of Shigella flexneri 2a O-specific polysaccharide-tetanus toxoid conjugates. Ann. N. Y. Acad. Sci. 730:359-360.
26. Raffatellu, M., et al. 2006. Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. Infect. Immun. 74:19-27.
27. Raffatellu, M., R. P. Wilson, S. E. Winter, and A. J. Baumler. 2008. Clinical pathogenesis of typhoid fever. J. Infect. Dev. Ctries. 2:260-266.
28. Rodriguez, M. E., et al. 1998. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine 16:1941-1949. (Pubitemid 28473940)
29. Shah, N. K. 2009. Indian conjugate Vi typhoid vaccine: do we have enough evidence? Indian Pediatr. 46:181-182.
30. Shinefield, H. R., et al. 2002. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr. Infect. Dis. J. 21:555-561.
31. Smith, P. K., et al. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76-85.
32. Snape, M. D., et al. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173-184.
33. Snellings, N. J., E. M. Johnson. D. J. Kopecko, H. H. Collins, and L. S. Baron. 1981. Genetic regulation of variable Vi antigen expression in a strain of Citrobacter freundii. J. Bacteriol. 145:1010-1017.
34. Stein, K. E. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl. 1):S49-S52.
35. Steinhoff, M. C., et al. 1994. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J. 13:368-372.
36. Stone, A. L., and S. C. Szu. 1988. Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever. J. Clin. Microbiol. 26:719-725.
37. Szu, S. C., et al. 1989. Comparative immunogenicities of Vi polysaccharideprotein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun. 57:3823-3827.
38. Szu, S. C., X. R. Li, A. L. Stone, and J. B. Robbins. 1991. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59:4555-4561.
39. Szu, S. C., et al. 1994. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 62:4440-4444.
40. Tamm, E., et al. 2005. Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine 23:1715-1719. (Pubitemid 40215706)
41. Weintraub, A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 338:2539-2547.
42. World Health Organization. 2003. Background document: the diagnosis, treatment and prevention of typhoid fever. World Health Organization, Geneva, Switzerland.
43. World Health Organization. 2007. Background paper on vaccination against typhoid fever using new-generation vaccines - presented at the SAGE November 2007 meeting. World Health Organization, Geneva, Switzerland.
44. World Health Organization. 2008. Typhoid vaccines: WHO position paper. Wkly. Epidemiol. Rec. 83:49-59.